Search results
Results from the WOW.Com Content Network
Phenylbiguanide (PBG) is a 5-HT3 agonist used to study the role of 5-HT3 receptors in the central nervous system. [1] It has been found to trigger dopamine release in the nucleus accumbens of rats. [ 2 ]
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2]
The United States Drug Enforcement Administration (DEA) maintains lists regarding the classification of illicit drugs (see DEA Schedules).It also maintains List I of chemicals and List II of chemicals, which contain chemicals that are used to manufacture the controlled substances/illicit drugs.
The mechanism of action of biguanides is not fully understood, and many mechanisms have been proposed for metformin. [citation needed] Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. Therefore, they are effective in Type 2 diabetics; and in Type 1 diabetes when used in ...
The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a high potential for abuse. The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
Structure of chlorhexidine, a bisbiguanide antiseptic.. Bisbiguanides are a class of chemically related compounds known for their bactericidal properties. Generally considered to be of the generic formula: R 1 R 2 N.C(:NR 6)NH.C(:NH)NH.CH 2 X--(CH 2) 3 NH.C(:NH)NH.C(:NR 7)NR 3 R 4 V. [1] These compounds include the antiseptics chlorhexidine and alexidine.
meta-Chlorophenylbiguanide (1-(3-Chlorophenylbiguanide, m-CPBG) is an allosteric agonist and modulator of the 5-HT 3 receptor [1] [2] [3] and an antagonist of the α 2A-adrenergic receptor. [4] It has anxiogenic , emetic and hypothermic effects in animal studies.
In July 2016 α-PHiP was first identified as a designer drug [2] when it was reported to the EMCDDA by a forensic laboratory in Slovenia. [3] [4] It is a positional isomer of pyrovalerone, with the methyl group shifted from the 4-position of the aromatic ring to the 4-position of the acyl chain. Similarly to other cathinones, use of α-PiHP can ...